Institute of Orthopedics and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, 310006, China.
The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
J Orthop Surg Res. 2024 Jan 19;19(1):80. doi: 10.1186/s13018-023-04391-3.
Low back pain (LBP) is a common orthopedic disease over the world. Lumbar intervertebral disc degeneration (IDD) is regarded as an important cause of LBP. Shensuitongzhi formula (SSTZF) is a drug used in clinical treatment for orthopedic diseases. It has been found that SSTZF can have a good treatment for IDD. But the exact mechanism has not been clarified. The results showed that SSTZF protects against LSI-induced degeneration of cartilage endplates and intervertebral discs. Meanwhile, SSTZF treatment dramatically reduces the expression of inflammatory factor as well as the expression of catabolism protein and upregulates the expression of anabolism protein in LSI-induced mice. In addition, SSTZF delayed the progression of LSI-induced IDD via downregulation the level of NF-κB signaling key gene RELA and phosphorylation of key protein P65 in endplate chondrocytes. Our study has illustrated the treatment as well as the latent mechanism of SSTZF in IDD.
下背痛(LBP)是全球常见的骨科疾病。腰椎间盘退变(IDD)被认为是 LBP 的重要原因。身痛逐瘀汤方(SSTZF)是一种用于骨科疾病临床治疗的药物。已经发现 SSTZF 对 IDD 有很好的治疗作用。但其确切机制尚不清楚。结果表明,SSTZF 可防止 LSI 诱导的软骨终板和椎间盘退变。同时,SSTZF 治疗可显著降低 LSI 诱导的小鼠中炎症因子以及分解代谢蛋白的表达,并上调合成代谢蛋白的表达。此外,SSTZF 通过下调终板软骨细胞中 NF-κB 信号关键基因 RELA 和关键蛋白 P65 的磷酸化水平,延缓了 LSI 诱导的 IDD 的进展。本研究阐明了 SSTZF 在 IDD 中的治疗作用及其潜在机制。
Osteoarthritis Cartilage. 2023-5
Spine (Phila Pa 1976). 2015-2-15
Front Bioeng Biotechnol. 2024-10-28
Quant Imaging Med Surg. 2023-5-1
Osteoarthritis Cartilage. 2023-9